Downstream coronary effects of drug-eluting stents.

dc.contributor.author

Krasuski, Richard A

dc.contributor.author

Cater, George M

dc.contributor.author

Devendra, Ganesh P

dc.contributor.author

Wolski, Kathy

dc.contributor.author

Shishehbor, Mehdi H

dc.contributor.author

Nissen, Steven E

dc.contributor.author

Oberti, Carlos

dc.contributor.author

Ellis, Stephen G

dc.coverage.spatial

United States

dc.date.accessioned

2015-12-03T17:44:01Z

dc.date.issued

2011-10

dc.description.abstract

BACKGROUND: Antiproliferative agents used in drug-eluting stents (DES) attenuate atherosclerosis, yet DES implantation has been linked to endothelial dysfunction. The downstream effects of DES on new lesion formation have not been previously directly examined. We sought to compare the development of de novo stenoses and need for treatment in the downstream coronary vessel of patients treated with DES or a bare-metal stent. METHODS: Angiographic images and procedural information were prospectively collected on 463 adults who underwent implantation of a single stent in a proximal coronary artery, had an appropriate control vessel for comparison, and subsequently returned for intervention. Propensity matching identified 89 pairs of patients. End points were defined as angiographic identification of a de novo stenosis or need for secondary intervention in the downstream vessel within 12 months of initial intervention. RESULTS: In the overall (P < .01) and propensity-matched cohort (P = .01), there was reduced risk of new lesions downstream to DES. No difference was seen in respective control vessels (P = .14 and P = .99). A reduced need for downstream intervention with DES was seen in both the overall (P = .01) and propensity-matched cohorts (P = .04). No difference was seen in the control vessels (P = .98 and P = .36). Multivariate proportional hazards modeling of known atherosclerosis risk factors identified stent type as the sole predictor for downstream lesions (P < .01) and downstream events (P = .02). CONCLUSIONS: Patients receiving DES appear less likely to develop downstream stenoses and events compared with patients receiving bare-metal stents, suggesting beneficial downstream drug delivery.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/21982671

dc.identifier

S0002-8703(11)00572-2

dc.identifier.eissn

1097-6744

dc.identifier.uri

https://hdl.handle.net/10161/11022

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Am Heart J

dc.relation.isversionof

10.1016/j.ahj.2011.08.001

dc.subject

Aged

dc.subject

Coronary Restenosis

dc.subject

Coronary Stenosis

dc.subject

Drug-Eluting Stents

dc.subject

Female

dc.subject

Humans

dc.subject

Male

dc.subject

Middle Aged

dc.subject

Prospective Studies

dc.title

Downstream coronary effects of drug-eluting stents.

dc.type

Journal article

duke.contributor.orcid

Krasuski, Richard A|0000-0003-3150-5215

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/21982671

pubs.begin-page

764

pubs.end-page

771.e1

pubs.issue

4

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Cardiology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

162

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Stent Downstream.pdf
Size:
730.22 KB
Format:
Adobe Portable Document Format
Description:
Published version